Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1995 1
1997 2
2000 1
2016 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.
Cohn SM, Lipsett PA, Buchman TG, Cheadle WG, Milsom JW, O'Marro S, Yellin AE, Jungerwirth S, Rochefort EV, Haverstock DC, Kowalsky SF. Cohn SM, et al. Among authors: jungerwirth s. Ann Surg. 2000 Aug;232(2):254-62. doi: 10.1097/00000658-200008000-00016. Ann Surg. 2000. PMID: 10903605 Free PMC article. Clinical Trial.
Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S. Genovese MC, et al. Among authors: jungerwirth s. Arthritis Rheumatol. 2016 Dec;68(12):2857-2866. doi: 10.1002/art.39808. Arthritis Rheumatol. 2016. PMID: 27390150 Free PMC article. Clinical Trial.
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy.
Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, Khan N, Pangan AL, Jungerwirth S, Keystone EC. Kremer JM, et al. Among authors: jungerwirth s. Arthritis Rheumatol. 2016 Dec;68(12):2867-2877. doi: 10.1002/art.39801. Arthritis Rheumatol. 2016. PMID: 27389975 Free PMC article. Clinical Trial.
The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Nifedipine Study Group.
Glasser SP, Ripa SR, Allenby KS, Schwartz LA, Commins BM, Jungerwirth S. Glasser SP, et al. Among authors: jungerwirth s. Clin Ther. 1995 Mar-Apr;17(2):296-312. doi: 10.1016/0149-2918(95)80028-x. Clin Ther. 1995. PMID: 7614530 Clinical Trial.